Pharmacokinetics of HR17031 Injection in Healthy Subjects

• Status: Active, not recruiting
• Trial end date: 2021-10-08
• Target enrollment: 0
• Participant gender: All

Summary

To compare the pharmacokinetics and safety of HR17031 injection, SHR20004 injection and/or INS068 injection in healthy subjects

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Criteria

Inclusion Criteria:

1. Body mass index (BMI) ranges from 18 to 27 kg/m2 (both ends included), and the body weight is ≥50 kg for men and ≥45 kg for women；

2. Fasting blood glucose during the screening is < 6.1 mmol/L；

Exclusion Criteria:

1. It has clinical significance for abnormalities Laboratory examination, if there is a clear reasonable reason, can be retested within a week, with the retest results Whether the subject meets the requirements

2. Severe systemic disease, or a prior history of pancreatitis or other systemic problems within 1 month prior to screening;

3. Participate in any clinical trial of a drug or medical device within 3 months prior to screening (subject to signed informed consent)